Therapy-induced apoptosis in primary tumors
1Department of Cancer Biology-173, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. dmcconke@mdanderson.org
Abstract:
An enormous body of literature has accumulated over the past 15 years implicating apoptosis (programmed cell death) in breast cancer cell death induced by conventional and investigational cancer therapies in preclinical models. As a result, new therapeutic approaches that directly target key components of apoptotic pathways are either entering or will soon enter clinical trials in patients, raising hopes that the information gained from the preclinical studies can be translated to improve patient care. However, there is a new appreciation for the fact that apoptosis is not the only relevant pathway that mediates physiological cell death, and many investigators are challenging the notion that targeting apoptosis is the best means of optimizing therapeutic efficacy in primary tumors. Here I will review some of the basic concepts that have emerged from the study of apoptosis in preclinical models, the evidence that apoptosis does or does not mediate the effects of current front line therapies in patients, and the new strategies that are emerging that are designed to more directly target apoptotic pathways.
Insights
Apoptosis, or programmed cell death, is crucial for breast cancer therapy efficacy. However, targeting apoptosis alone may not be optimal, as other cell death pathways are being explored for improved cancer treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Extensive research over 15 years links apoptosis (programmed cell death) to breast cancer cell death from various therapies in preclinical models.
- This has led to the development of new therapies targeting apoptotic pathways, now entering clinical trials.
Purpose of the Study:
- To review basic concepts of apoptosis in preclinical breast cancer models.
- To examine the evidence for apoptosis mediating current therapies in patients.
- To discuss emerging strategies targeting apoptotic pathways.
Main Methods:
- Literature review of preclinical studies on apoptosis in breast cancer.
- Analysis of clinical trial data and patient studies on therapy-induced cell death.
- Synthesis of emerging therapeutic strategies targeting cell death pathways.
Main Results:
- Preclinical models strongly implicate apoptosis in therapy-induced breast cancer cell death.
- Clinical evidence suggests apoptosis may not solely mediate the effects of all current therapies in patients.
- Alternative cell death pathways are gaining recognition for therapeutic potential.
Conclusions:
- While apoptosis is a key pathway, it may not be the sole determinant of therapeutic success in breast cancer.
- Future breast cancer treatment strategies may benefit from targeting multiple cell death pathways beyond apoptosis.
- Further research is needed to fully understand and leverage diverse cell death mechanisms for improved patient outcomes.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
01:17The Extrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy